Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f209ef5eb0bf426bf7278483ca9befc4 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4747 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
filingDate |
2004-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2010-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b84a92d26001ae890bf99cbc5fd27646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_818da2d5e63a858c43a94093fab4bb8a |
publicationDate |
2010-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-7687465-B2 |
titleOfInvention |
Therapeutic cancer vaccine |
abstract |
The present invention relates to polypeptides capable of raising a specific T-cell response, wherein the polypeptide comprises a peptide consisting of at least 9 consecutive amino acid residues of ML-IAP, as well as to the use of such polypeptides as medicaments. The invention furthermore relates to use of such polypeptides for treatment of a clinical condition, such as cancer. The invention also relates to methods of selecting a peptide comprising a peptide fragment of ML-IAP for use in a vaccine compositions as well as to vaccine compositions comprising isolated ML-IAP (SEQ ID NO:1) and/or one or more polypeptide fragments thereof. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11414458-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017274038-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9770513-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10568926-B2 |
priorityDate |
2003-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |